EHA scientific workshop report: the role of epigenetics in hematological malignancies.
The clinical application of targeting the epigenome in cancer cells through demethylation and histone acetylation is an exiting novel pharmacologic concept in the treatment of malignant diseases. The manipulation of gene expression through epigenetic modifications represents a new strategy in targeted anti-cancer therapy. A workshop was held in Cannes, France in February 2007 to discuss the latest findings in basic and clinical research regarding the role of epigenetics in haematological malignancies. Fundamental aspects of DNA methylation, the histone code, chromatin remodelling and transcriptional regulatory mechanisms were discussed. Recent technological advances are now allowing scientists to gain further insight in the altered epigenome during tumorigenesis and will provide numerous opportunities for translational research. The aim of this article is to summarize the major topics discussed at the workshop by leading experts in the field and highlight conclusions for future basic, translational and clinical research.
Jost
Edgar
E
Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Aachen, Germany.
Galm
Oliver
O
D000107:Acetylation; D004273:DNA, Neoplasm / Q000235:genetics; D044127:Epigenesis, Genetic / Q000235:genetics*; D005602:France; D019337:Hematologic Neoplasms / Q000235:genetics*; D006657:Histones / Q000378:metabolism; D006801:Humans; D009154:Mutation
D004273:DNA, Neoplasm; D006657:Histones